論文・技術情報追加のお知らせ

1. Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.

トルバプタン使用における肝胆道・腎・代謝障害のリスク

対象DB：FAERS

2. Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database.

エクリズマブの副作用に関する新たな知見

対象DB：FAERS

3. High-risk adverse events in two types of single inhaler triple-therapy: a pharmacovigilance study based on the FAERS database.

BUD/GLY/FORはデバイス使用問題、FF/UMEC/VIは肺炎リスク高

対象DB：FAERS

4. Analysis of the risk of oncological adverse events associated with infliximab in combination with azathioprine compared to monotherapy: insights from the FAERS database.

インフリキシマブ単独療法では併用療法が腫瘍リスクを低減

対象DB：FAERS

5. Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib.

ソトラシブ使用者において肝胆道系障害が多発

対象DB：FAERS

6. The Safety Profile of Amiodarone Among Older Adults (age >/= 75 years): A Pharmacovigilance Study from the FDA Data.

アミオダロンは高齢者で間質性肺疾患や徐脈が多く報告

対象DB：FAERS

7. Sodium-glucose cotransporter 2 inhibitor treatment has differential effects on the incidence of various malignancies: Evidence from a spontaneous adverse reaction database.

SGLT2阻害薬は膵臓癌・腎臓癌に関連し、乳癌などを減少

対象DB：FAERS

8. The safety of cyclosporine and tacrolimus in pediatric nephrotic syndrome patients: a disproportionate analysis based on the FAERS database.

シクロスポリンは腎毒性、タクロリムスは代謝障害

対象DB：FAERS

9. Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database.

ゾルゲンスマの副作用、肝酵素上昇や血小板減少を発見

対象DB：FAERS

10. Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database.

スタチンの肝毒性に関する新たなシグナルを発見

対象DB：FAERS

11. Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS.

セルメチニブで新たな副作用シグナル、早期管理重要

対象DB：FAERS

12. Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.

薬剤による尿閉報告増加、要監視

対象DB：CVAR,FAERS

13. Adverse events associated with IL-23 and IL-12/23 inhibitors in the clinical management of psoriasis: a comprehensive pharmacovigilance analysis.

IL-23/IL-12/23阻害薬の副作用、感染症リスクあり

対象DB：FAERS

14. A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.

パリペリドンパルミテートの副作用分析、性別差異あり

対象DB：FAERS,JADER

15. A Real-World Data Analysis of Alglucosidase Alfa in the FDA Adverse Event Reporting System (FAERS) Database.

アルグルコシダーゼアルファの副作用解析

対象DB：FAERS

16. Analysis of Drug-Related Tinnitus Based on the FDA Adverse Event Reporting System Database.

薬剤による耳鳴りの副作用解析

対象DB：FAERS

17. Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS.

パーキンソン様症状に関連する薬剤を解析

対象DB：FAERS

18. Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance.

アミバンタマブの安全性評価結果

対象DB：FAERS

19. A disproportionality analysis of FDA adverse event reporting system events for misoprostol.

ミソプロストールの副作用を分析

対象DB：FAERS

20. Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-analysis and Pharmacovigilance Study.

小児患者におけるFXa阻害剤の副作用を分析

対象DB：FAERS

21. A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database.

ファリシマブの副作用分析

対象DB：FAERS

22. A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.

ブロダルマブのRWDでの安全性を評価

対象DB：FAERS

23. Second-generation antipsychotic-induced dystonia: Analysis using the Japanese Adverse Drug Event Report (JADER) database.

SGAごとのジストニアリスクに性別や発症時期が影響

対象DB：JADER

24. Analyses of Adverse Drug Reactions to Fluoroquinolones in Spontaneous Reports Before and After the Referral and in Clinical Routine Cases.

フルオロキノロンの副作用報告に違いは少なく、薬剤ごとに特徴が見られた

対象DB：EudraVigilance

25. From bench to bedside: elucidating VEGF(R) inhibitor-related heart failure in cancer treatment.

VEGF(R)iによる心不全の臨床特徴と分子メカニズムを解明

対象DB：VigiBase

26. Clinical Relatedness and Stability of vigiVec Semantic Vector Representations of Adverse Events and Drugs in Pharmacovigilance.

vigiVecの安定性と臨床関連性を評価

対象DB：VigiBase

27. Use of biologics to treat asthma during pregnancy and adverse events in pregnant women and newborns: A global pharmacovigilance analysis.

妊婦への生物製剤使用に関する安全性評価

対象DB：VigiBase

28. Influence of Nursing Time and Staffing on Medication Errors: A Cross-Sectional Analysis of Administrative Data.

看護師の業務負担が薬剤ミスと関連

対象DB：DPC

29. Effectiveness of Oral Prophylactic Antibiotics for Diagnostic Bronchoscopy: A Nationwide Database Study.

診断的気管支鏡検査で抗生物質予防が感染を減少

対象DB：DPC

30. In-hospital mortality of patients admitted to the intermediate care unit in hospitals with and without an intensive care unit: a nationwide inpatient database study.

ICUのない病院のIMCU入院は死亡率増加

対象DB：DPC

31. Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis.

日本の潰瘍性大腸炎治療に課題、コスト削減が必要

対象DB：MDV

32. Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.

日本の多発性骨髄腫治療に変化、抗CD38抗体増加

対象DB：MDV

33. Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation.

アリピプラゾールは代謝面で有利だが効果は同等

対象DB：CPRD

34. Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study.

SGLT-2iは認知症リスクと無関係

対象DB：CPRD

35. Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study.

GLP-1 RAでHbA1c改善は限定的

対象DB：CPRD

36. The Impact of Idiopathic Intracranial Hypertension on Cardiovascular Disease Risk Among UK Women: An Obesity-Adjusted Analysis.

IIHは肥満とは別に心血管リスクを増加

対象DB：THIN